RedHill Biopharma Ltd (RDHL) has released an update.
RedHill Biopharma Ltd. has announced a new Chinese patent for opaganib, a host-directed therapeutic agent with potential applications including Ebola virus inhibition, valid through 2035. U.S. Army studies highlight opaganib’s promise as the first host-directed molecule to demonstrate in vivo activity against Ebola, with a significant survival rate increase. The drug, which is in development for a variety of indications, is notable for its oral administration, resistance to viral mutations, and potential in pandemic and nuclear/chemical exposure scenarios.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
